Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes
Open Access
- 8 October 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (19) , 5215-5224
Abstract
Exposure to cancer therapies is associated with an increased risk of clonal hematopoiesis (CH). The objective of our study was to investigate the genesis and evolution of CH after cancer therapy. In this prospective study, we undertook error-corrected duplex DNA sequencing in blood samples collected before and at 2 time points after chemoradiation in patients with esophageal or lung cancer recruited from 2013 to 2018. We applied a customized workflow to identify the earliest changes in CH mutation count and clone size and determine their association with clinical outcomes. Our study included 29 patients (87 samples). Their median age was 67 years, and 76% (n = 22) were male; the median follow-up period was 3.9 years. The most mutated genes were DNMT3A, TET2, TP53, and ASXL1. We observed a twofold increase in the number of mutations from before to after treatment in TP53, which differed from all other genes examined (P < .001). Among mutations detected before and after treatment, we observed an increased clone size in 38% and a decreased clone size in 5% of TP53 mutations (odds ratio, 3.7; 95% confidence interval [CI], 1.75-7.84; P < .001). Changes in mutation count and clone size were not observed in other genes. Individuals with an increase in the number of TP53 mutations after chemoradiation experienced shorter overall survival (hazard ratio, 7.07; 95% CI, 1.50-33.46; P = .014). In summary, we found an increase in the number and size of TP53 CH clones after chemoradiation that were associated with adverse clinical outcomes.Keywords
This publication has 38 references indexed in Scilit:
- Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general populationCancer Cell, 2023
- Causes of Clonal Hematopoiesis: a ReviewCurrent Oncology Reports, 2023
- Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and TreatmentCurrent Oncology Reports, 2022
- Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta‐analysisAmerican Journal of Hematology, 2022
- Clonal hematopoiesis before, during, and after human spaceflightCell Reports, 2021
- Clonal Hematopoiesis Before, During, and After Human SpaceflightCell Reports, 2020
- Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2019
- Universal Patterns of Selection in Cancer and Somatic TissuesCell, 2017
- Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCell Stem Cell, 2017
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyThe Lancet Oncology, 2017